Yumanity Therapeutics, Inc. (YMTX)
|Net Income (ttm)||-38.80M|
|Trading Day||January 22|
|Day's Range||19.51 - 20.18|
|52-Week Range||0.89 - 22.52|
BOSTON, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (Nasdaq: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modif...
Shares of Yumanity to commence trading on Nasdaq under new ticker symbol “YMTX” on December 23, 2020
Yumanity Therapeutics discovers and develops disease-modifying therapies for neurodegenerative diseases. It focuses on discovering disease-modifying therapies for patients with Parkinson's, amyotrophic lateral sclerosis, and Alzheimer's diseases. The company concentrates on reversing the cellular phenotypes and disease pathologies caused by protein misfolding. Yumanity Therapeutics Inc. has a strategic research collaboration and license agreement with Merck. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
|IPO Date |
Feb 11, 2016
|Stock Exchange |
|Ticker Symbol |
In 2019, YMTX's revenue was $5.00 million, an increase of 76.06% compared to the previous year's $2.84 million. Losses were -$59.13 million, -4.38% less than in 2018.